Stockscreener 앱 받기
11.85
0.59%
0.07
시간 외 거래:
12.00
0.15
+1.27%
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
How to recover losses in Ocular Therapeutix Inc. stock2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Why analysts upgrade Ocular Therapeutix Inc. stockJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Is Ocular Therapeutix Inc. stock oversold or undervaluedMarket Activity Report & Fast Moving Stock Watchlists - newser.com
Using Ichimoku Cloud for Ocular Therapeutix Inc. technicalsGap Down & Fast Moving Stock Watchlists - newser.com
Analyzing drawdowns of Ocular Therapeutix Inc. with statistical toolsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
Ocular Therapeutix Inc. stock trendline breakdownWall Street Watch & Expert Curated Trade Ideas - newser.com
Real time pattern detection on Ocular Therapeutix Inc. stockWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
How risky is Ocular Therapeutix Inc. (0OT) stock compared to peersRecession Risk & Weekly Chart Analysis and Guides - newser.com
What momentum shifts mean for Ocular Therapeutix Inc.Market Trend Report & High Return Trade Guides - newser.com
Todd Anderman Sells 11,132 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
FY2025 EPS Estimate for Ocular Therapeutix Raised by Analyst - MarketBeat
Ocular Therapeutix chief legal officer Anderman sells $137k in stock - Investing.com Canada
How to track smart money flows in Ocular Therapeutix Inc.July 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Using AI based signals to follow Ocular Therapeutix Inc.Earnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Can Ocular Therapeutix Inc. stock maintain growth trajectoryTrade Volume Report & Low Risk Profit Maximizing Plans - newser.com
Ocular Therapeutix (NASDAQ:OCUL) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
What machine learning models say about Ocular Therapeutix Inc.IPO Watch & Trade Opportunity Analysis - newser.com
Published on: 2025-10-10 03:24:04 - newser.com
Using R and stats models for Ocular Therapeutix Inc. forecastingMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Is Ocular Therapeutix Inc. (0OT) stock considered safe haven2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Price action breakdown for Ocular Therapeutix Inc.2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
WilmerHale Advised Ocular Therapeutix™ in $475 Million Underwritten Offering - WilmerHale
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL): HC Wainwright & Co. Raises Price Targ - GuruFocus
Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 - Yahoo Finance
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale - MSN
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 Shares - MarketBeat
What analysts say about Ocular Therapeutix Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
Why Ocular Therapeutix Inc. (0OT) stock is trending on social mediaLong Setup & Technical Pattern Alert System - newser.com
Ocular Therapeutix (OCUL) Is Down 8.9% After $475M Equity Raise to Fund Axpaxli Trials — Has the Bull Case Changed? - Sahm
Exit strategy if you’re trapped in Ocular Therapeutix Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - newser.com
Will Ocular Therapeutix Inc. stock deliver long term returns2025 Momentum Check & Technical Pattern Recognition Alerts - newser.com
Published on: 2025-10-05 03:10:01 - newser.com
Looking at the Changing Narrative for Ocular Therapeutix After Recent Analyst Updates - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by Zacks Research - MarketBeat
Ocular Therapeutix (OCUL): Exploring Valuation as Investor Interest Grows in Biotech Prospects - Sahm
Ocular Therapeutix (OCUL) Analyst Rating Update: Piper Sandler Raises Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (OCUL) Receives Upgraded Price Target from Ba - GuruFocus
Baird Maintains Ocular Therapeutix (OCUL) Outperform Recommendation - Nasdaq
Published on: 2025-10-02 20:18:07 - newser.com
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Analyst Rating Update: Chardan Capital Maintains Buy | OCUL Stock News - GuruFocus
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL) - The Globe and Mail
Needham Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.2%Here's Why - MarketBeat
Needham Raises Price Target for OCUL, Maintains Buy Rating | OCU - GuruFocus
Needham & Company LLC Raises Ocular Therapeutix (NASDAQ:OCUL) Price Target to $20.00 - MarketBeat
JMP Securities Maintains Ocular Therapeutix (OCUL) Market Outperform Recommendation - Nasdaq
Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says - MarketScreener
1.11%
자본화:
|
볼륨(24시간):